Personalized, tumor‐informed, circulating tumor DNA assay for detecting minimal residual disease in non‐small cell lung cancer patients receiving curative treatments
Thoracic Cancer · 2024-05 · 15 (13) · 1095-1102
DOI: 10.1111/1759-7714.15281 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2024-04. Verfasst von Youjin Oh und 12 weiteren Autor:innen. Beteiligte Einrichtung: Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Circulating Tumor DNA, Neoplasm, Residual, Lung Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Circulating tumor DNA (ctDNA) has emerged as a prognostic and predictive biomarker for detection of minimal residual disease (MRD), monitoring treatment response, and early detection of recurrence in cancer patients. In this study, we explored the utility of ctDNA‐based MRD detection to predict recurrence in a real‐world cohort of primarily early‐stage non‐small cell lung cancer (NSCLC) patients treated with curative intent.
Methods
Longitudinal plasma samples were collected post curative‐intent treatment from 36 patients with stage I–IV NSCLC. A personalized, tumor‐informed assay was used to detect and quantify ctDNA in plasma samples.
Results
Of the 24 patients with plasma samples available during the MRD window (within 6 months of curative surgery and before adjuvant therapy), ctDNA was detectable in two patients. Patients with ctDNA‐positivity during the MRD window were 15 times more likely to recur compared to ctDNA‐negative patients (HR: 15.0, 95% CI: 1.0–253.0, p = 0.010). At any time post‐curative intent treatment, ctDNA‐positivity was associated with significantly poorer recurrence‐free survival compared to persistently ctDNA‐negative patients ( p < 0.0001).
Conclusion
Our real‐world data indicate that longitudinal, personalized, tumor‐informed ctDNA monitoring is a valuable tool in patients with NSCLC receiving curative treatment to identify patients at high risk for recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
- Department of internal medicine, John H. Stroger Hospital of Cook County, Chicago, Illinois, USA.
- North Central Bronx Hospital, Albert Einstein College of Medicine, Bronx, New York, USA.
- Kyungpook National University School of Medicine, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea.
- Baylor University, Waco, Texas, USA.
- Natera, Inc., Austin, Texas, USA.
ORCID-Profile: Youjin Oh, Jeeyeon Lee, Liam Il-Young Chung, Charuta C Palsuledesai, Young Kwang Chae
Zitieren
APA
Oh, Y., Yoon, S. M., Lee, J., Park, J. H., Lee, S., Hong, T., Chung, L. I., Sudhaman, S., Riddell, T., Palsuledesai, C. C., Krainock, M., Liu, M. C., & Chae, Y. K. (2024). Personalized, tumor‐informed, circulating tumor DNA assay for detecting minimal residual disease in non‐small cell lung cancer patients receiving curative treatments. Thoracic Cancer, 15(13), 1095-1102. https://doi.org/10.1111/1759-7714.15281
Vancouver
Oh Y, Yoon SM, Lee J, Park JH, Lee S, Hong T, et al. Personalized, tumor‐informed, circulating tumor DNA assay for detecting minimal residual disease in non‐small cell lung cancer patients receiving curative treatments. Thoracic Cancer. 2024;15(13):1095-1102. doi:10.1111/1759-7714.15281
BibTeX
@article{Oh2024,
author = {Oh, Youjin and Yoon, Sung Mi and Lee, Jeeyeon and Park, Joo Hee and Lee, Soowon and Hong, Timothy and Chung, Liam Il-Young and Sudhaman, Sumedha and Riddell, Timothy and Palsuledesai, Charuta C and Krainock, Michael and Liu, Minetta C and Chae, Young Kwang},
title = {Personalized, tumor‐informed, circulating tumor DNA assay for detecting minimal residual disease in non‐small cell lung cancer patients receiving curative treatments},
journal = {Thoracic Cancer},
year = {2024},
volume = {15},
number = {13},
pages = {1095--1102},
doi = {10.1111/1759-7714.15281}
}
EUVIMED